NO20044091L - Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase - Google Patents

Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase

Info

Publication number
NO20044091L
NO20044091L NO20044091A NO20044091A NO20044091L NO 20044091 L NO20044091 L NO 20044091L NO 20044091 A NO20044091 A NO 20044091A NO 20044091 A NO20044091 A NO 20044091A NO 20044091 L NO20044091 L NO 20044091L
Authority
NO
Norway
Prior art keywords
preparation
oxdiazol
alkoxy
phenyl
substituted
Prior art date
Application number
NO20044091A
Other languages
English (en)
Inventor
Guenter Mueller
Hubert Heuer
Stefan Petry
Karl Schoenafinger
Armin Bauer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20044091L publication Critical patent/NO20044091L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives anvendelse av substituerte 3-fenyl-5-alkoksy-l,3,4-oksdiazol-2-oner, samt deres farmakologisk godtagbare salter og syreaddisjonssalter for fremstilling av legemidler som viser en hemmende virkning på den pankreatiske lipase, PL.Videre beskrives anvendelse av forbindelser med formel 1 der restene har de nærmere angitte betydninger, samt deres farmasøytisk godtagbare salter og syreaddisjonssalter for fremstilling av et legemiddel for profylakse eller terapi av obesitas eller diabetes mellitus Type 1 og 2.
NO20044091A 2002-02-28 2004-09-27 Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase NO20044091L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208986A DE10208986A1 (de) 2002-02-28 2002-02-28 Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
PCT/EP2003/001560 WO2003072098A1 (de) 2002-02-28 2003-02-17 Verwendung substituierter 3-phenyl-5-alkoxy-1,3,4-oxdiazol-2-one zur herstellung von arzneimitteln mit hemmender wirkung an der pankreatischen lipase

Publications (1)

Publication Number Publication Date
NO20044091L true NO20044091L (no) 2004-09-27

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044091A NO20044091L (no) 2002-02-28 2004-09-27 Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase

Country Status (20)

Country Link
EP (1) EP1482929A1 (no)
JP (1) JP2005519079A (no)
KR (1) KR20040101250A (no)
CN (1) CN1638766A (no)
AR (1) AR038702A1 (no)
AU (1) AU2003210292A1 (no)
BR (1) BR0308045A (no)
CA (1) CA2477005A1 (no)
CO (1) CO5611144A2 (no)
DE (1) DE10208986A1 (no)
HR (1) HRP20040783A2 (no)
HU (1) HUP0500093A2 (no)
IL (1) IL163719A0 (no)
MA (1) MA27173A1 (no)
MX (1) MXPA04007480A (no)
NO (1) NO20044091L (no)
PL (1) PL371310A1 (no)
RU (1) RU2004128932A (no)
TW (1) TW200400026A (no)
WO (1) WO2003072098A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
MX2007004889A (es) 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
US7923462B2 (en) * 2007-12-25 2011-04-12 Kissei Pharmaceutical Co., Ltd. Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
AR074978A1 (es) 2008-12-23 2011-03-02 Bial Portela & Ca Sa 3-n-aril-1,3,4-oxadiazolonas 5-o-sustituidas para uso en el tratamiento del dolor y procedimiento de obtencion
CN103086859B (zh) * 2011-11-08 2015-11-11 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
AU2018326396B2 (en) * 2017-09-01 2023-10-26 Falasca, Marco PROF Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleolyl-LPI) and uses thereof
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
JP7681030B2 (ja) * 2020-02-07 2025-05-21 サイトキネティックス， インコーポレイテッド Ｎａｍｐｔモジュレーター

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
AU784827B2 (en) * 2000-03-07 2006-06-29 Sanofi-Aventis Deutschland Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase

Also Published As

Publication number Publication date
RU2004128932A (ru) 2005-04-10
PL371310A1 (en) 2005-06-13
KR20040101250A (ko) 2004-12-02
CO5611144A2 (es) 2006-02-28
EP1482929A1 (de) 2004-12-08
HUP0500093A2 (hu) 2005-04-28
AR038702A1 (es) 2005-01-26
IL163719A0 (en) 2005-12-18
MA27173A1 (fr) 2005-01-03
JP2005519079A (ja) 2005-06-30
HRP20040783A2 (en) 2005-04-30
MXPA04007480A (es) 2004-11-10
TW200400026A (en) 2004-01-01
CA2477005A1 (en) 2003-09-04
AU2003210292A1 (en) 2003-09-09
BR0308045A (pt) 2004-12-21
WO2003072098A1 (de) 2003-09-04
DE10208986A1 (de) 2003-09-11
CN1638766A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20060908L (no) Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse
NO20050648L (no) Heterocyklisk substituerte benzoylureaer, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20051871L (no) Opioidreseptorantagonister
NO20052883L (no) Nye medikamenter for behandling av kronisk obstruktiv luftveissykdom.
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
NO20072389L (no) Substituerte benzokinolizinderivater
WO2005082414A3 (en) Concomitant drugs of a sulfonamide and another therapeutic agent
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20052914L (no) Terapeutiske forbindelser
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
NO20065904L (no) Terapeutiske forbindelser
SE0202429D0 (sv) Novel Compounds
NO20054868L (no) CaSr antagonist
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application